Curia: Advancing Solutions For Rare Diseases

With over 6,000 identified rare diseases, millions of people face challenges in diagnosis and treatment. 1 in 5 cancers is rare, and 70% of rare diseases begin in childhood- yet treatment options remain limited.

At Curia, we are dedicated to advancing solutions for rare diseases through API innovation, including offering Ganaxolone API for regulatory purposes. Ganaxolone represents one of the many ways we’re supporting the development of therapies that can make a real difference in the lives of those affected.

Because behind every rare disease statistic is a person, a family, and a story worth fighting for.

Discover how Curia’s API capabilities, including Ganaxolone, are helping advance the treatment of rare diseases.